Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Aquatic Capital Management LLC

Aquatic Capital Management LLC raised its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 5,283.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 129,209 shares of the company's stock after acquiring an additional 126,809 shares during the period. Aquatic Capital Management LLC owned about 0.10% of Apellis Pharmaceuticals worth $4,123,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Xponance Inc. grew its holdings in shares of Apellis Pharmaceuticals by 5.6% in the fourth quarter. Xponance Inc. now owns 14,072 shares of the company's stock worth $449,000 after purchasing an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares in the last quarter. Signaturefd LLC lifted its position in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after purchasing an additional 918 shares during the period. US Bancorp DE boosted its stake in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after purchasing an additional 1,327 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Apellis Pharmaceuticals by 9.4% during the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock valued at $691,000 after buying an additional 1,864 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the sale, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 6,115 shares of company stock worth $154,684 in the last ninety days. 6.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on APLS. JPMorgan Chase & Co. increased their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. The Goldman Sachs Group decreased their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Scotiabank increased their price target on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research note on Wednesday, April 2nd. Wedbush decreased their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $45.28.

Apellis Pharmaceuticals Trading Up 4.5 %

Shares of APLS traded up $0.87 during midday trading on Thursday, reaching $20.08. The company had a trading volume of 3,850,175 shares, compared to its average volume of 2,165,621. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.98 and a 1-year high of $49.06. The stock has a market cap of $2.52 billion, a PE ratio of -9.89 and a beta of 0.85. The firm has a 50 day simple moving average of $21.97 and a 200-day simple moving average of $27.42. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period last year, the company earned ($0.73) EPS. Research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).